Digital Public Defence: Kirsti Aas
Cand. Med Kirsti Aas at Institute of Clinical Medicine will be defending the thesis Prostate Cancer without Distant Metastases Treatment and Mortality in Norway 2001-2016 for the degree of PhD (Philosophiae Doctor).
Photo: Moment Studio.
The public defence will be held as a video conference over Zoom.
The defence will follow regular procedure as far as possible, hence it will be open to the public and the audience can ask ex auditorio questions when invited to do so.
Due to copyright reasons, an electronic copy of the thesis must be ordered from the faculty. In order for the faculty to have time to process the order, it must be received by the faculty no later than 2 days prior to the public defence. Orders received later than 2 days before the defence will not be processed. Inquiries regarding the thesis after the public defence must be addressed to the candidate.
Digital Trial Lecture – time and place
- First opponent: Clinical Professor Michael Borre, Aarhus University Hospital
- Second opponent: Associate Professor Helena Bertilsson, St. Olavs Hospital, University Hospital of Trondheim
- Third member and chair of the evaluation committee: Professor Arild Nesbakken, University of Oslo
Chair of the Defence
Professor Øyvind Sverre Bruland, University of Oslo
Associate professor Viktor Berge, University of Oslo
Prostate cancer is the most common cancer in Norwegian males, and the majority of men have no distant metastases at the time of diagnosis. These men are potential candidates for curative treatment with radical prostatectomy or radiotherapy. In this project we used population-based data from the Cancer Registry of Norway to investigate prognostic factors, treatment and mortality in men diagnosed with prostate cancer without distant metastases in 2001-2016.
Based on ten years observation, we found that patients were two times more likely to die from other causes than from prostate cancer (prostate cancer-specific mortality (PCSM) 8.5% vs overall mortality 25.5%), this discrepancy decreased with increasing risk group. Curative treatment reduced PCSM, and the greatest survival benefit was observed in high-risk patients. Gleason score was the strongest predictor of PCSM. After five years of observation, senior adults (>70 years) diagnosed with high-risk prostate cancer had similar prostate cancer- and overall survival benefits from curative treatment compared to younger men (<70 years). Over time, we observed an increase in the proportion of high-risk patients treated with curative intent, along with a decrease in PCSM. Both these trends were more prominent in senior men.
Increasing time to prostatectomy within six months of diagnosis did not worsen the pathological findings in the prostatectomy specimen or increase the use of post-prostatectomy radiotherapy or death from prostate cancer.
Contact the research support staff.